SAMD1 suppresses epithelial-mesenchymal transition (EMT) pathways in pancreatic ductal adenocarcinoma

SAMD1 (SAM-domain containing protein 1), a CpG island-binding protein, plays a pivotal role in the repression of its target genes. Despite its significant correlation with outcomes in various tumor types, the role of SAMD1 in cancer has remained largely unexplored. In this study we focused on pancreatic ductal adenocarcinoma (PDAC) and revealed that SAMD1 acts as a repressor of genes associated with epithelial-mesenchymal transition (EMT). Upon deletion of SAMD1 in PDAC cells, we observed significantly increased migration rates. SAMD1 exerts its effects by binding to specific genomic targets, including CDH2, encoding N-cadherin, which emerged as a driver of enhanced migration upon SAMD1 knockout. Furthermore, we discovered the FBXO11-containing E3 ubiquitin ligase complex as an interactor of SAMD1. FBXO11 ubiquitinates SAMD1 within its DNA-binding winged helix domain and inhibits SAMD1 chromatin binding genome-wide. High FBXO11 expression in PDAC is associated with poor prognosis and increased expression of EMT-related genes, underlining an antagonistic relationship between SAMD1 and FBXO11. In summary, our findings provide new insights into the regulation of EMT-related genes in PDAC, shedding light on the intricate role of SAMD1 and its interplay with FBXO11 in this cancer type.

[1]  C. Sotiriou,et al.  Pharmacological targeting of netrin-1 inhibits EMT in cancer , 2023, Nature.

[2]  Robert Liefke,et al.  Investigation of SAMD1 ablation in mice , 2023, Scientific Reports.

[3]  Stephen S. Gisselbrecht,et al.  The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain , 2022, Nucleic acids research.

[4]  R. Kooy,et al.  Non-Mendelian inheritance patterns and extreme deviation rates of CGG repeats in autism , 2022, Genome research.

[5]  Kevin A. Murach,et al.  Muscle-Specific Cellular and Molecular Adaptations to Late-Life Voluntary Concurrent Exercise , 2022, Function.

[6]  Christopher B. Barnett,et al.  The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2022 update , 2022, Nucleic Acids Res..

[7]  Dongfeng Ge,et al.  Ultrasound-targeted microbubble destruction-mediated silencing of FBXO11 suppresses development of pancreatic cancer , 2022, Human Cell.

[8]  T. Stiewe,et al.  The CpG Island-Binding Protein SAMD1 Contributes to an Unfavorable Gene Signature in HepG2 Hepatocellular Carcinoma Cells , 2022, Biology.

[9]  A. Brazma,et al.  The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..

[10]  A. Jemal,et al.  Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics , 2021, Journal of the National Cancer Institute.

[11]  Robert Liefke,et al.  Making fundamental scientific discoveries by combining information from literature, databases, and computational tools – An example , 2021, Computational and structural biotechnology journal.

[12]  M. Bulyk,et al.  The SAM domain-containing protein 1 (SAMD1) acts as a repressive chromatin regulator at unmethylated CpG islands , 2021, Science Advances.

[13]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[14]  B. Győrffy,et al.  Pancancer survival analysis of cancer hallmark genes , 2020, Scientific Reports.

[15]  Shondra M. Pruett-Miller,et al.  FBXO11-Mediated Proteolysis of BAHD1 Relieves PRC2-dependent Transcriptional Repression in Erythropoiesis. , 2020, Blood.

[16]  G. Sethi,et al.  The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges , 2019, Cells.

[17]  I. Sahin,et al.  Pancreatic cancer microenvironment: a current dilemma , 2019, Clinical and Translational Medicine.

[18]  A. Melnick,et al.  ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. , 2018, Cancer cell.

[19]  Shuai Huang,et al.  Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review , 2017, BioMed research international.

[20]  M. Bulyk,et al.  Polycomb-like proteins link the PRC2 complex to CpG islands , 2017, Nature.

[21]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[22]  Xin Hu,et al.  FBXO11 promotes ubiquitination of the Snail family of transcription factors in cancer progression and epidermal development. , 2015, Cancer letters.

[23]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[24]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[25]  Fidel Ramírez,et al.  deepTools: a flexible platform for exploring deep-sequencing data , 2014, Nucleic Acids Res..

[26]  Timothy E. Reddy,et al.  Distinct properties of cell-type-specific and shared transcription factor binding sites. , 2013, Molecular cell.

[27]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[28]  K. Olive,et al.  Pancreatic cancer: why is it so hard to treat? , 2013, Therapeutic advances in gastroenterology.

[29]  Nathan C. Sheffield,et al.  The accessible chromatin landscape of the human genome , 2012, Nature.

[30]  T. Hudson,et al.  The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma , 2012, Nature Reviews Gastroenterology &Hepatology.

[31]  A. Bird,et al.  CpG islands and the regulation of transcription. , 2011, Genes & development.

[32]  Cory Y. McLean,et al.  GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.

[33]  Robert S. Illingworth,et al.  CpG islands influence chromatin structure via the CpG-binding protein Cfp1 , 2010, Nature.

[34]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[35]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[36]  W. Gu,et al.  FBXO11 Promotes the Neddylation of p53 and Inhibits Its Transcriptional Activity* , 2007, Journal of Biological Chemistry.

[37]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[39]  L. Derycke,et al.  N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. , 2004, The International journal of developmental biology.

[40]  M. Imamura,et al.  N-Cadherin Expression and Epithelial-Mesenchymal Transition in Pancreatic Carcinoma , 2004, Clinical Cancer Research.

[41]  B. Jacobsen,et al.  Cloning of a Mammalian Transcriptional Activator That Binds Unmethylated CpG Motifs and Shares a CXXC Domain with DNA Methyltransferase, Human Trithorax, and Methyl-CpG Binding Domain Protein 1 , 2000, Molecular and Cellular Biology.

[42]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[43]  M. Shipp,et al.  FBXO 11 targets BCL 6 for degradation and is inactivated in diffuse large B-cell lymphomas , 2011 .

[44]  M. Hollingsworth,et al.  ADH‐1 suppresses N‐cadherin‐dependent pancreatic cancer progression , 2008, International journal of cancer.